Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

Terminated

• Conditions: Hereditary Breast and Ovarian Cancer; Adnexal Mass; Germline BRCA1 Gene Mutation; Germline BRCA2 Gene Mutation

• Registration Number: NCT04668521
• Lead Sponsor: Aspira Women's Health

Brief Summary

The objective of this project is to validate a next-generation assay that utilizes both the protein biomarkers of our already established ovarian cancer risk assessment combined with a molecular profile in both germline and early somatic detection.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-05-04
• Study First Submitted: 2020-12-09
• Study First Submitted QC: 2020-12-09
• Study First Posted: 2020-12-16
• Status Verified: 2023-12
• Primary Completion: 2023-12-15
• Study Completion: 2023-12-15
• Last Update Submitted: 2023-12-19
• Last Update Posted: 2023-12-26

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 215

Inclusion Criteria

Not provided

Exclusion Criteria

• n/a

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
OVA360	12 months	Identify the molecular key driver of Ovarian cancer and develop a diagnostic test for early Ovarian cancer detection

Trial Locations

Locations (1)

Silvana Franco; 🇺🇸 Austin, Texas, United States